CDK5 and colorectal adenocarcinoma: When we analyzed the progression-free interval (PFI), an endpoint similar to DFS and TTP used in our previous analysis which has been shown to be the most reliable endpoint when analyzing data from the TCGA-colorectal adenocarcinoma (COAD) database [21], we found that high Cdk5 in the CMS1 correlated with poorer outcomes (p = 0.036, 95% CI 1.07–8.10) (Figure 6C), while no differences were found in the three remaining molecular subtypes (Figure S5B).